TRT Side Effects: What to Expect

Table of Contents

Testosterone replacement therapy (TRT) can cause both common side effects, such as acne and fluid retention, and more serious risks, including elevated red blood cell counts and fertility suppression.^1,2 The likelihood and severity of these effects vary depending on the individual, the prescribed dose, and the delivery method used. Regular monitoring through blood work and clinical follow-up helps detect emerging problems early and allows clinicians to adjust treatment before side effects become serious.^1,2

At a Glance

What it is: TRT is a medically prescribed therapy to restore testosterone levels
Common side effects: Acne, fluid retention, mood changes, and mild hormonal adjustments³
Serious risks: Elevated red blood cell count, cardiovascular considerations, and fertility suppression
Monitoring: Regular blood testing helps manage and reduce risks
Timeline: Side effects may appear early and stabilize with treatment adjustments
Key misconception: Not all side effects occur in every patient, and risks vary by individual

What Are the Side Effects of TRT?

In the context of hormone therapy, side effects refer to any physiological changes that occur as a result of altering the body’s testosterone levels. Some of these changes are expected parts of hormonal adjustment. Others represent potential complications that require clinical attention.

The distinction matters. Mild acne during the first few weeks of treatment, for example, falls into the category of expected adjustment.³ A significant rise in hematocrit (the percentage of red blood cells in the blood) is a less common, but more serious side effect that may need intervention.^1-3

Side effect severity and risk vary between individuals. Factors like age, pre-existing health conditions, genetic predisposition, and baseline hormone levels all contribute to this variability.^1,4-7 Understanding this range helps patients set realistic expectations and communicate more effectively with their healthcare provider.

Common Side Effects of Testosterone Replacement Therapy

Most common TRT side effects are mild, manageable, and often temporary. They tend to appear within the first weeks to months of treatment as the body adjusts to new hormone levels.

Acne and oily skin are among the most frequently reported effects.³ Testosterone stimulates sebaceous gland activity, which can increase oil production and lead to breakouts, particularly on the face, back, and shoulders. This is more common in patients who had acne-prone skin before starting therapy and often improves as levels stabilize.

Fluid retention can cause mild swelling in the ankles or a feeling of puffiness.³ This occurs because testosterone influences sodium and water balance in the body. It is usually modest and may resolve on its own or with minor dose adjustments.

Breast tenderness or mild enlargement (gynecomastia) can develop when a portion of exogenous testosterone converts to estradiol, a form of estrogen, through a process called aromatization.³ This is generally mild and may not require treatment, though persistent or bothersome cases should be reported to a clinician.

Mood changes are variable. Some patients report increased irritability, restlessness, or emotional fluctuation during the early weeks of therapy. Others experience improvements in mood as testosterone levels normalize. These changes are usually transient. However, significant mood disturbances, including increased aggression or depressive symptoms, should prompt a conversation with a healthcare provider.

Mild sleep changes, including disrupted sleep or changes in sleep quality, may occur early in treatment.^1,3 In some cases, testosterone therapy may worsen pre-existing obstructive sleep apnea (a condition in which breathing repeatedly stops and starts during sleep), though the evidence on this association is mixed.

These common effects are generally not reasons to stop therapy. They do, however, warrant discussion with a prescribing clinician, who can determine whether dose or formulation changes are appropriate.

Serious Risks and Complications

Serious risks associated with TRT are less common than the mild side effects described above, but they carry greater clinical significance. Understanding them in context, including how they are monitored and managed, helps patients weigh the risk-to-benefit ratio with their provider.

Polycythemia (elevated hematocrit)

Polycythemia is one of the most well-documented serious side effects of TRT.¹ Testosterone stimulates erythropoiesis, the production of red blood cells. When hematocrit rises too high (typically above 50–54%, depending on the clinical guideline) blood viscosity (thickness) increases, which raises the theoretical risk of blood clots, stroke, and other thromboembolic events.

This risk is dose-dependent and more pronounced with injectable formulations, which tend to produce higher peak testosterone levels. Polycythemia is the most common reason clinicians reduce a TRT dose, switch formulations, or temporarily suspend treatment. Regular hematocrit monitoring is considered essential by the Endocrine Society.⁸

Cardiovascular considerations

The relationship between TRT and cardiovascular risk has been one of the most debated topics in endocrinology over the past decade.¹ Earlier observational studies suggested a possible increase in heart attack and stroke risk, while other studies found no increased risk or even modest cardiovascular benefit in certain populations.

The TRAVERSE trial,⁹ a large randomized controlled study published in 2023, found that TRT in men with hypogonadism and pre-existing or high risk for cardiovascular disease did not significantly increase the incidence of major adverse cardiovascular events compared to placebo. This provided some reassurance, but it may not be applicable to everyone, and long-term outcomes beyond its follow-up period remain uncertain.

The FDA requires a general warning on testosterone products regarding potential cardiovascular risk.¹⁰ Clinicians typically assess each patient’s cardiovascular risk profile before initiating therapy and continue monitoring throughout treatment.

Fertility suppression

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, a hormonal feedback loop that regulates sperm production. When the body receives testosterone from an external source, it reduces its own production of gonadotropins, which are the hormones that signal the testes to produce sperm. This can lead to significantly reduced sperm counts or azoospermia (the complete absence of sperm).^1-2

This effect is generally reversible after discontinuing TRT, though recovery time varies and is not guaranteed in all cases. For men who wish to preserve fertility, clinicians may recommend alternatives to exogenous testosterone, such as clomiphene citrate or human chorionic gonadotropin (hCG), rather than standard TRT.

Prostate-related concerns

TRT can stimulate growth of existing prostate tissue. This raises concern in men with undiagnosed prostate cancer or benign prostatic hyperplasia (BPH, a non-cancerous enlargement of the prostate).^1-2,8

PSA (prostate-specific antigen) levels are monitored before and during TRT. A rapid or significant rise in PSA may prompt further evaluation, including referral to a urologist. The Endocrine Society recommends against initiating TRT in men with untreated, locally advanced, or metastatic prostate cancer.⁸

How TRT Side Effects Change Over Time

Side effects from TRT do not remain static.^1-2 They follow a general pattern of early onset, adjustment, and long-term stabilization, though the timeline varies from one person to the next.

Early adjustment phase (weeks 1–6): This is when many common side effects first appear. Acne, fluid retention, mood fluctuation, and changes in energy or libido are typical during this window. The body is responding to a new hormonal baseline. These effects are generally not cause for alarm unless they are severe or worsen rapidly.

Stabilization phase (months 2–6): As serum testosterone levels become more consistent, especially once dose titration is complete, many early side effects start to improve. Acne may improve, fluid retention often resolves, and mood tends to level out. However, this is also the period when hematocrit may begin to climb, making the first follow-up blood work particularly important.

Long-term phase (6 months and beyond): With ongoing monitoring and appropriate dose management, most patients reach a stable state in which side effects are minimal. Some risks, however, require indefinite surveillance. Hematocrit, PSA, and lipid levels should be reassessed periodically as long as therapy continues. Long-term TRT risks are not fully characterized for all populations, which is why ongoing clinical follow-up remains a standard part of responsible treatment.

How Monitoring Reduces Risk

Regular monitoring is not optional with TRT; it is a core component of safe treatment. Blood work and clinical assessments allow providers to detect problems before they become serious and to adjust therapy based on objective data.

What gets tested and when

The Endocrine Society recommends baseline labs before starting TRT, follow-up testing at 3–6 months after initiation, and periodic testing thereafter, typically every 6–12 months once stable.⁸

Key markers include:

Hematocrit and hemoglobin: to monitor for polycythemia
Serum testosterone levels: to confirm the dose is achieving the target range (typically 300–1,000 ng/dL, depending on the guideline and the lab)
PSA: to screen for prostate changes
Lipid panel: to assess cardiovascular markers
Estradiol: to evaluate for excessive aromatization
Liver function: especially relevant for oral formulations

How dose adjustments reduce risk

If hematocrit rises above acceptable thresholds, the clinician may reduce the dose, switch to a formulation with less peak-trough variation (such as a gel instead of injections), or temporarily pause therapy. Similarly, if testosterone levels consistently exceed the upper target range, reducing the dose can lower the risk of dose-dependent side effects like polycythemia, mood disturbance, and fluid retention.

Making monitoring concrete

For patients, monitoring typically involves a blood draw at a lab, followed by a review of results with the prescribing clinician either in person or via telehealth. The process is straightforward but essential. Patients who skip follow-up testing are at higher risk for undetected complications.

How Delivery Method Affects Side Effects

TRT is available in several formulations, and the delivery method influences both the pattern of testosterone absorption and the likelihood of certain side effects.^1-2

Intramuscular injections (typically testosterone cypionate or enanthate) are the most commonly prescribed form. They produce a peak in testosterone levels shortly after injection, followed by a gradual decline until the next dose. This peak-trough pattern is associated with a higher incidence of polycythemia compared to other methods. Some patients also report mood fluctuation tied to these hormonal swings, particularly toward the end of the injection cycle.

Topical gels provide a more stable daily testosterone level because they are applied once daily. They are associated with fewer peak-related side effects but carry a risk of transdermal transfer, meaning testosterone can be inadvertently passed to others through skin contact, particularly to women and children. Proper application and hand-washing after use are important.

Transdermal patches also offer more stable delivery. They may cause skin irritation at the application site, which is their most common side effect. Adhesion problems can also affect absorption consistency.

Subcutaneous pellets are implanted under the skin every 3–6 months and provide sustained testosterone release. They avoid the daily compliance requirement but can cause local complications such as infection or pellet extrusion at the insertion site.

Oral and nasal formulations are less commonly used. Newer oral formulations (such as testosterone undecanoate) have been designed to reduce the liver toxicity associated with older oral testosterone preparations, though they may still carry gastrointestinal side effects.

Choosing a delivery method involves balancing convenience, side effect profile, cost, and individual health factors. This decision is best made collaboratively between patient and healthcare professional.

Who May Be at Higher Risk

Not all patients carry the same level of risk when starting TRT. Several factors can increase vulnerability to side effects or complications.

Pre-existing cardiovascular disease: Patients with a history of heart attack, stroke, or established cardiovascular disease should undergo careful risk-benefit evaluation before starting TRT. While the TRAVERSE trial provided reassurance that TRT did not significantly increase major cardiovascular events in a high-risk population, individual circumstances vary.⁹

Elevated baseline hematocrit: Patients who already have hematocrit levels near the upper limit of normal may reach dangerous thresholds more quickly on TRT.^1-2 This is particularly relevant for people who live at high altitude or have conditions like chronic obstructive pulmonary disease (COPD) that may independently elevate red blood cell counts.

Obstructive sleep apnea: Untreated or poorly controlled sleep apnea may be exacerbated by testosterone therapy. The Endocrine Society recommends screening for sleep apnea before initiating TRT in men with obesity or symptoms suggestive of the condition.⁸

Prostate cancer history or elevated PSA: Men with a history of prostate cancer or unexplained PSA elevations require urological evaluation before starting TRT. Active prostate cancer is considered a contraindication.^1,2,8

Men trying to conceive: Because TRT suppresses sperm production, men who are planning to father children should discuss alternative approaches with their provider before initiating standard testosterone therapy.^1,2,8

Age and general health: Older adults and those with multiple comorbidities may metabolize testosterone differently and may be more susceptible to fluid retention, cardiovascular strain, or prostate effects.^1,2,8 These patients benefit from more conservative dosing and closer monitoring.

What to Expect After Starting TRT: A Clinical Timeline

Understanding what happens and when after starting TRT helps set realistic expectations and reduces unnecessary anxiety about normal adjustment effects.

Week 1–2: Most patients do not notice dramatic changes immediately. Some may experience increased energy or subtle mood shifts. Injection-site soreness or mild skin irritation (with gels or patches) may be the earliest noticeable effects.

Weeks 2–6: Common early side effects are most likely to appear during this window. Acne, oily skin, mild fluid retention, breast tenderness, and changes in mood or libido may develop. These are typically manageable and often temporary. Some patients report improved sleep and energy, while others feel slightly off-balance as hormone levels adjust.

Months 2–4: The clinician will typically order the first follow-up blood work during this period. Testosterone levels are assessed to confirm appropriate dosing. Hematocrit is checked for early signs of polycythemia. If side effects are present, a dose adjustment may be made. Many early side effects begin to stabilize.

Months 4–6: Most patients who will respond well to TRT are experiencing consistent benefits by this point, with side effects diminished or resolved. Hematocrit may still be climbing gradually, so continued monitoring is important.

6 months and beyond: Ongoing maintenance blood work, typically every 6–12 months, continues as long as therapy is in place. PSA, hematocrit, lipid levels, and testosterone are reassessed at each interval. New symptoms at any point should be reported to the prescribing clinician.

When to Contact a Healthcare Provider

Some side effects are expected and manageable. Others require prompt medical attention. Knowing the difference is important for any patient on TRT.

Contact a provider promptly if any of the following occur:

Sudden chest pain, shortness of breath, or signs of a cardiovascular event
Severe, persistent headaches or vision changes (possible signs of markedly elevated hematocrit or blood pressure)
Significant swelling in the legs, particularly if asymmetric (possible sign of a blood clot)
Rapid or unexplained weight gain with severe edema
Difficulty breathing during sleep or new onset of loud snoring (potential worsening of sleep apnea)
Severe mood changes, including suicidal thoughts, pronounced aggression, or major depressive symptoms
Difficulty urinating or noticeable changes in urinary patterns (possible prostate-related issue)
Signs of allergic reaction, including rash, hives, or swelling at the injection or application site that worsens

Symptoms that warrant a non-urgent follow-up include mild but persistent acne, ongoing fluid retention that does not resolve, breast tenderness that worsens over time, or libido changes that are concerning to the patient.

When in doubt, contacting the prescribing clinician is always appropriate. Patients should not adjust or discontinue TRT on their own without medical guidance, as abrupt cessation can cause withdrawal symptoms and hormonal disruption.

Frequently Asked Questions

Most common TRT side effects, such as acne and fluid retention, are not permanent and often improve with dose adjustments or as your body adapts to treatment. Some effects, like fertility suppression, typically reverse after stopping TRT, though recovery timelines vary. If a side effect persists or concerns you, your clinician can evaluate whether a change in dose, formulation, or treatment plan is appropriate.

The earliest side effects you may notice include increased oily skin, mild acne, subtle mood changes, or slight fluid retention. These usually occur within the first two to six weeks. Some people also report changes in energy or libido during this initial period. Not everyone experiences the same effects, and the timing depends on your dose, delivery method, and individual physiology.

The evidence on this question has been mixed. Some earlier observational studies raised concern about increased cardiovascular risk, but the 2023 TRAVERSE trial found no significant increase in major adverse cardiovascular events among men with hypogonadism and pre-existing or elevated cardiovascular risk. The FDA still requires a cardiovascular risk warning on testosterone products. You should discuss your individual cardiovascular risk profile with your provider before starting TRT.

Yes, TRT can suppress sperm production, sometimes to the point of azoospermia, meaning no sperm are present in the ejaculate. This happens because exogenous testosterone signals your body to reduce its own production of the hormones that drive sperm development. Fertility typically recovers after stopping TRT, but the timeline is unpredictable and full recovery is not guaranteed. If you are planning to conceive, discuss this with your doctor before starting therapy.

Yes, the delivery method affects which side effects are more likely. Injections tend to cause more peak-related effects like mood fluctuation and carry a higher risk of polycythemia, while gels provide steadier levels but introduce a risk of skin transfer to others. Patches may cause local skin irritation, and pellets can occasionally result in infection or extrusion at the insertion site. Your clinician can help you choose the formulation that best fits your health profile and lifestyle.

Most guidelines recommend baseline blood work before starting TRT, a follow-up at 3–6 months, and then periodic testing every 6–12 months once your levels are stable. Your specific schedule depends on your clinician’s assessment, your lab results, and whether any dose changes have been made. Key markers that are typically checked include hematocrit, testosterone levels, and PSA.

You should contact your doctor promptly if you experience chest pain, sudden shortness of breath, severe headaches, leg swelling (especially if one-sided), major mood disturbances, difficulty urinating, or signs of an allergic reaction. These may indicate serious complications that require evaluation and possible treatment adjustment or discontinuation. Do not stop TRT abruptly on your own, but rather work with your healthcare provider to manage any changes safely.

Not necessarily. Many side effects appear early and improve as your body adjusts or as your clinician optimizes your dose. However, some risks, like gradual hematocrit elevation, can develop or accumulate over time, which is why ongoing monitoring is essential. Whether side effects worsen, stabilize, or resolve depends on your individual response, the adequacy of monitoring, and how well your treatment plan is managed.

Conclusion

TRT can be a beneficial therapy for men with clinically diagnosed hypogonadism, but it carries real side effects and risks that deserve informed attention. Common effects like acne, fluid retention, and mood changes are typically manageable and often resolve with time or dose adjustments. Serious risks, including polycythemia, cardiovascular considerations, fertility suppression, and prostate-related concerns, require ongoing surveillance through regular blood work and clinical follow-up.

Not every patient experiences the same side effects, and individual risk depends on health history, age, baseline lab values, and delivery method. Anyone considering or currently using TRT should discuss their full medical history, risk factors, and treatment goals with a qualified healthcare provider.

References

Barbonetti A, D’Andrea S, Francavilla S. Testosterone replacement therapy. Andrology. 2020;8(6):1551-1566. https://onlinelibrary.wiley.com/doi/10.1111/andr.12774
Wang C, Swerdloff RS. Testosterone Replacement Therapy in Hypogonadal Men. Endocrinol Metab Clin North Am. 2022;51(1):77-98. https://www.sciencedirect.com/science/article/abs/pii/S0889852921001055
Basheer B, Ila V, Barros R, Mesquita F, Lopes LS, Lima VFN, Favorito LA, Ramasamy R. Management of Adverse Effects in Testosterone Replacement Therapy. Int Braz J Urol. 2025;51(3):e20259904. https://www.intbrazjurol.com.br/pdf/vol51n03/IBJU20259904.pdf
Mlynarz N, Miedziaszczyk M, Wieckowska B, Szalek E, Lacka K. Effects of Testosterone Replacement Therapy on Metabolic Syndrome in Male Patients-Systematic Review. Int J Mol Sci. 2024;25(22):12221. https://www.mdpi.com/1422-0067/25/22/12221
Tabei SS, Kataria R, Hou S, Singh A, Al Hameedi H, Hasan D, Hsieh M, Raheem OA. Testosterone replacement therapy in patients with cachexia: a contemporary review of the literature. Sex Med Rev. 2024;12(3):469-476. https://doi.org/10.1093/sxmrev/qeae031
Lenfant L, Leon P, Cancel-Tassin G, Audouin M, Staerman F, Rouprêt M, Cussenot O. Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer. Urol Oncol. 2020;38(8):661-670. https://linkinghub.elsevier.com/retrieve/pii/S1078-1439(20)30151-4
Skiba R, Rymarz A, Matyjek A, Dymus J, Woźniak-Kosek A, Syryło T, Zieliński H, Niemczyk S. Testosterone Replacement Therapy in Chronic Kidney Disease Patients. Nutrients. 2022;14(16):3444. https://www.mdpi.com/2072-6643/14/16/3444
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://academic.oup.com/jcem/article/103/5/1715/4939465
Hackett GI. Long Term Cardiovascular Safety of Testosterone Therapy: A Review of the TRAVERSE Study. World J Mens Health. 2025;43(2):282-290. https://doi.org/10.5534/wjmh.240081
U.S. Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products